Gilead Sciences, Inc. (FRA:GIS)
Germany · Delayed Price · Currency is EUR | Market Cap | 132.59B |
| Revenue (ttm) | 24.58B |
| Net Income (ttm) | 5.37B |
| Shares Out | n/a |
| EPS (ttm) | 4.27 |
| PE Ratio | 24.67 |
| Forward PE | 14.73 |
| Dividend | 2.82 (2.66%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 120 |
| Average Volume | 297 |
| Open | 100.24 |
| Previous Close | 101.64 |
| Day's Range | 100.24 - 105.90 |
| 52-Week Range | 78.88 - 111.04 |
| Beta | n/a |
| RSI | 68.01 |
| Earnings Date | Nov 6, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlan...
Gilead's Trodelvy cuts breast cancer risk by 38% in trial
Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as an initial treatment, according to trial results presented on Sunday.
Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-f...
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically m...
Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run
Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.
Notable Friday Option Activity: RGA, LQDA, GILD
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Reinsurance Group of America, Inc. (Symbol: RGA), where a total of 2,005 contracts have tra...
Validea Detailed Fundamental Analysis - GILD
Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published strateg...
Insider Sell Alert: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)
Insider Sell Alert: Johanna Mercier Sells Shares of Gilead Sciences Inc (GILD)
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE: MRK) on Wednesday announced ad...
ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial
Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference
Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV innovat...
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from Octob...
GILD Quantitative Stock Analysis
Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published strateg...
Noteworthy ETF Outflows: SPMO, GILD, MS, CME
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Momentum ETF (Symbol: SPMO) where we have detected an ...
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
Arcus Biosciences reports 26.7-month median survival ... Full story available on Benzinga.com
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic ...
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Rob Sechan , CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ: GILD) as his final trade. Lending support to his choice, Citigroup analyst Geoff M...
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will demonstrate progress in our commitment to transform how cancer is treated with new data at t...
3 Defensive Stocks to Watch as Trade Tensions Resurface: GILD, JNJ, KR
With investors on edge as the world's two largest economies go head-to-head again, seeking out stocks that can offer defensive safety in the portfolio may be necessary
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
The Investment Committee give you their top stocks to watch for the second half.
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eas...
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October ...